Viral Liver Diseases. Current Status of Therapy Viral liver diseases, particularly hepatitides of type B (HBV) and C (HCV) show an increasing trend, the number of infected people in the world being several hundred million people. With the exception of other forms (HAV, HDV, HEV, and HGV), where infectivity is also high, possible transmission and infection in HBV and HCV are often independent of the affected person (blood transfusion, stomatological operations, surgery, etc.). Treatment of hepatitides not proceeding into a chronic stage is without any problems at the moment. In the case of HBV, besides chemical drugs which are being developed, vaccination is available. Hepatitis C remains to be a problem of world importance. Its growth in recent years runs parallel to an increase in drug addicts and HIV infection. The difficulties in the development of vaccines are related to rapid mutation of the virus and continuous formation of other serotypes. Progress in many biological disciplines is a certain warranty that the so-called NS3 proteases inhibitors and medicaments of other types, including vaccines, will be introduced into practice for HCV treatment.

        Key words: hepatitis – drugs – treatment